GlassScriptPhysician profile
Andrew K Springer
NPI 1790967123
$2,166.65
in general payments reported to CMS, 2019-2025
25 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $183 · 2023: $609 · 2024: $684 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.68 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.71 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $297.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.49 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Medical Device Business Services, INC. | $137.01 | 2025 | Stratafix |
| Neurocrine Biosciences, INC. | $126.50 | 2025 | |
| Lucid Diagnostics INC. | $122.68 | 2024 | |
| Amgen INC. | $119.49 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $119.15 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $112.90 | 2021-2025 | Shingrix |
| Lilly USA, LLC | $95.63 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $74.63 | 2023-2025 | |
| Gilead Sciences, INC. | $55.05 | 2023-2024 | |
| Dynavax Technologies Corporation | $49.76 | 2023-2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.70 | 2024 | Xifaxan |
| Amarin Pharma, INC. | $47.36 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.54 | 2022-2024 | |
| Abbott Laboratories | $43.71 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boston Scientific Corporation | $40.67 | 2025 | Watchman Access System |
| Idorsia Pharmaceuticals US INC | $23.92 | 2023 | Quviviq |
| Shield Therapeutics INC | $21.06 | 2023 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $19.63 | 2024 | |
| Vivus LLC | $18.73 | 2024 | Qsymia |
| Merck Sharp & Dohme LLC | $18.51 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $17.90 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.